2012 CMO Rankings

Featured Executive:

Michael Rosenblatt

Michael Rosenblatt is ExecRank's Top Chief Medical Officer for 2012. Mr. Rosenblatt’s experience in leading some of the best universities in the world and his strong record of success as a mediator between policymakers, physicians, and patients at Merck & Company have propelled him to number one on this year's list.

Michael Rosenblatt is Executive Vice President & Chief Medical Officer of Merck & Company. Dr. Rosenblatt has served as Dean of Tufts University School of Medicine. He previously held the appointment of George R. Minot Professor of Medicine at Harvard Medical School and Chief of the Division of Bone and Mineral Metabolism Research at Beth Israel Deaconess Medical Center. He served as the President of Beth Israel Deaconess Medical Center from 1999-2001 and was previously the Harvard Faculty Dean and Senior Vice President for Academic Programs at CareGroup and Beth Israel Deaconess Medical Center. He was also a founder of the Carl J. Shapiro Institute for Education and Research at Harvard Medical School and Beth Israel Deaconess Medical Center, a joint venture whose mission is to manage the academic enterprise and promote academic innovation.

Dean Rosenblatt has served as Director of the Harvard-MIT Division of Health Sciences and Technology, during which time he led a medical education organization for M.D., Ph.D., and M.D.-Ph.D. training jointly sponsored by Harvard and MIT. He was Senior Vice President for Research at Merck Sharp & Dohme Research Laboratories where he headed the worldwide development team for alendronate (FOSAMAX), Merck's bisphosphonate for osteoporosis and bone disorders. In addition, he directed drug discovery efforts in molecular biology, bone biology and calcium metabolism, virology, cancer research, lipid metabolism, and cardiovascular research in the United States, Japan, and Italy. In Japan, he had responsibility for clinical research and development. In leading most of Merck's international research efforts, he established two major basic research institutes, one in Tsukuba, Japan, and one near Rome, Italy. He also headed Merck Research's worldwide University and Industry Relations Department.

He is the recipient of the Fuller Albright Award for his work on parathyroid hormone and the Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman's Award from Merck. His research is in the field of hormonal regulation of calcium metabolism, osteoporosis, and cancer metastasis to bone. His major research projects are in the design of peptide hormone antagonists (especially parathyroid hormone), isolation/characterization of receptors and mapping hormone--receptor interactions, elucidating the mechanisms by which breast and prostate cancer "home" to bone, study of the tumor-secreted parathyroid hormone-like protein, and osteoporosis and bone biology.

2012 CMO Rankings

Share This

There are over 1,000 Chief Medical Officers in the United States. Only the very best are awarded the distinction of being a part of ExecRank’s “Top Chief Medical Officers Ranking” for 2012. The number one area of focus for CMOs in 2012 has been their ability to effectively manage research, development, patient safety, and the overall soundness of their health operations. ExecRank also weighed heavily the recommendations provided by CEOs and other executives of our finalists. In addition, we saw a significant uptick in the number of CMOs that served on boards of directors and gave speeches at trade shows throughout the year. The CMOs that made this list represent the best of the best in medical management and leadership for 2012.

CMOs were ranked according to our patent-pending proprietary CMO Ranking Algorithm that calculates points for 24 key categories, in addition to the insights and feedback from evaluation committees featuring some of the world’s most renowned business leaders. Like all of our position specific ranking algorithms, the CMO Ranking Algorithm serves as an objective standard for executive performance and is designed to produce results that act as leading indicators for future executive and team performance. Feedback from award winners includes:

Jeff Lauro, CIO, Collective Brands“I am honored to be included on ExecRank with such important leaders in my field.”

Denis Edwards, CIO Manpower Group“Thank you for honoring me and our outstanding team of IT professionals at ManpowerGroup. I am truly humbled to be included on a list that includes so many CIOs for whom I have the highest admiration and respect.”

Steve F. Brown – CIO Tenet Healthcare“I am truly honored to be among this distinguished group of IT leaders on ExecRank. My recognition is a reflection of the tremendous IT team at Tenet and the contributions of our key IT business partners Dell and Cerner Corporation.”

Tom Nightingale, ModusLink Global Solutions“It is great to see that ExecRank has produced a credible means to analyze the wide variety of techniques that exist across so many industries and produce a best-in-class rating system removing the subjectivity that has historically existed.”

Peter E. Holmes, Ph.D., Celanese Corporation“I am grateful to the nominating committee of ExecRank for this tremendous honor.”

See more praise and media mentions for ExecRank CIO rankings…

Chief Medical Officer

1. Michael Rosenblatt, Merck & Co., Inc. 2. Jonathan Perlin, HCA Holdings, Inc.
3. William Denman, General Electric Company 4. Scott Bruder, Stryker Corporation
5. David Durack, Becton, Dickinson and Company 6. Andrew Litt, Dell Inc
7. Robert London, Walgreen Co. 8. Barbara Paul, Community Health Systems
9. Stephane Allard, Epicept Corporation 10. Geeta Nayyar, AT&T
11. Camille Bedrosian, ALEXION PHARMACEUTICALS, INC. 12. Bob Wassman, Rosetta Genomics
13. Elliott Grossbard, Rigel Pharmaceuticals, Inc. 14. David Jin, BioTime, Inc.
15. Paul Billings, Life Technologies Corporation 16. Steven Fruchtman, Spectrum Pharmaceuticals Inc
17. Mohammad Azab, Astex Pharmaceuticals 18. Michael Lemp, Tearlab
19. Joanne Waldstreicher, Johnson & Johnson 20. Pamela Hymel, Walt Disney Company
21. Akshay Vaishnaw, Alnylam Pharmaceuticals, Inc. 22. Troyen Brennen, CVS Caremark Corporation
23. Samuel Nussbaum, WellPoint, Inc. 24. Jack Mahoney, Pitney Bowes Inc.
25. Alan Muney , CIGNA Corporation 26. Burt Adelman, DYAX CORP.
27. Pablo Lapuerta, Lexicon Pharmaceuticals 28. Patrice Rioux, Raptor Pharmaceuticals Corp.
29. Perry Nisen, GLAXOSMITHKLINE 30. Keith Dawkins, Boston Scientific Corporation
31. Robert Israel, Progenics Pharmaceuticals 32. Henry Fuchs, BIOMARIN PHARMACEUTICALS
33. Alan Bombard, Sequenom, Inc. 34. Bruce Scharschmidt, Hyperion Therapeutics Inc
35. Laurence Corash, Cerus 36. Freda Lewis-Hall, Pfizer
37. Michael Sweeney, DEPOMED, INC. 38. Stephen Peroutka, NeurogesX
39. Neil Frazer, Prima Biomed 40. Rankings Update, Inc.
41. Adam Craig, Sunesis Pharmaceuticals Inc. 42. Dave Mason, Given Imaging, Ltd.
43. Elliott Ehrich, ALKERMES 44. Jerome Zeldis, Celgene Corporation
45. Dexanne Clohan, HealthSouth Corporation 46. Frank Weber, Intermune Inc
47. Jeffrey Sherman, Horizon Pharma, Inc. 48. Gary Patou, PACIRA PHARMACEUTICALS, INC.
49. David Strayer, HEMISPHERX BIOPHARMA, INC. 50. Pamela Palmer, AcelRx Pharmaceuticals, Inc.
51. Anders Boss, MannKind Corporation 52. David Drutz, DARA BIOSCIENCES, INC.
53. Mark Frohlich, Dendreon Corporation 54. William Shanahan, Arena Pharmaceuticals
55. John Fort, POZEN Inc. 56. Bruce Feinberg, Cardinal Health
57. Robert Medve, Nektar Therapeutics 58. Karim Benali, ABIOMED, Inc.
59. Enrique Carrazana, ACORDA THERAPEUTICS 60. Lori Kunkel, Pharmacyclics
61. Krishna Kandarpa, Delcath Systems, Inc. 62. William Sheridan, BioCryst Pharmaceuticals, Inc.
63. Chuck Simonton, Abbott Laboratories 64. Stephen Kelsey, Geron Corporation
65. Thomas Davis, Celldex Therapeutics Inc. 66. John Fort, POZEN Inc.
67. Mark Sumeray, AEGERION PHARMACEUTICALS 68. Alan Krasner, Biodel Inc.
69. Scott Shikora, EnteroMedics Inc 70. Dawn McGuire, Opexa Therapeutics
71. Kent Bradley, Safeway 72. Nick Borys, Celsion Corporation
73. Pol Boudes, Amicus Therapeutics, Inc. 74. Peter Traber, Galectin Therapeutics, Inc.
75. Rankings Updates 76. Jonathan Cohen, Quest Diagnostics
77. Santosh Vetticaden, Cubist Pharmaceuticals, Inc 78. Paul Foster, CARDIUM THERAPEUTICS
79. Tillman Pearce, Threshold Pharmacueticals 80. Tim Moore, Web M.D.
81. Michael Kurman, Cleveland Biolabs, Inc. 82. Allen NISSENSON, DaVita
83. Tim Garnett, Eli Lilly and Company 84. Mark Breacher, LabCorp
85. Eugene Sullivan , United Therapeutics 86. Tyler Martin, Dynavax Technologies Corporation
87. Karin Hehenberger, Coronado Biosciences, Inc. 88. Dale Ando, Sangamo Biosciences Inc.
89. Daniel Hoffman, CNS Response, Inc. 90. Kemal Malik, Bayer
91. Ken Somberg, Covance Inc. 92. Tom Reynolds, Seattle Genetics Inc.
93. Richard Levy, INCYTE CORPORATION 94. Michael Tarnoff, Covidien
95. Gail Brown, Telik, Inc. 96. Chris O’Brien, Neurocrine Biosciences
97. Maurizio Voi, Curis, Inc. 98. Ken Krantz, NovaBay Pharmaceuticals, Inc.
99. Roy Beveridge, McKesson Corporation 100. Gisela Schwab, Exelixis
101. Kamran Hosseini, InSite Vision 102. Glenn Pierce, Biogen Idec
103. Randall Kaye, AVANIR PHARMACEUTICALS 104. Brian Bernick, TherapeuticsMD
105. Kazuko Matsuda, MediciNova, Inc. 106. Elaine Mischler, Fiserv, Inc.
107. Peter Powchik, Regeneron 108. Karston Witt, Array BioPharma
109. Kelvin Baggett, Tenet Healthcare Corporation 110. Tage Ramakrishna, VALEANT
111. Richard Sanchez, Molina Healthcare, Inc. 112. Lane Donnelly, Nemours Children’s Hospital
113. Andrew Allen, Clovis Oncology, Inc. 114. Sally Brooks, Kindred Healthcare, Inc.
115. Anthony Kotin, Magellan Health Services, Inc. 116. Michael Severino, Amgen
117. Ira Lawrence, Medicis Pharmaceutical Corporation 118. Lee Allen, AMAG PHARMACEUTICALS
119. Jeffrey Tobias, JAZZ PHARMACEUTICALS PLC 120. Steven Benner, Cell Therapeutics, Inc
121. Raymond Hoffman, Mosaic 122. Mayzie Johnston, GTX Inc.
123. Jonathan Lord, Humana 124. Lanny Copeland, Lifepoint Hospitals Inc.
125. Marc Miller, SeaBright Holdings, Inc. 126. William Slichenmyer, wslichenmyer@aveopharma.com
127. Rankings Update 128. Patrick Mooney, Echo Therapeutics, Inc.
129. Rankings Update

130. Rankings Update
131. Colin Rudolph, MEAD JOHNSON NUTRITIONALS 132. Larry Reisman, Aetna Inc.
133. Hemal Shah, OPTIMER PHARMACEUTICALS, INC. 134. Alexander Zukiwski, Arno Therapeutics, Inc.
135. Gail Comer, Synergy Pharmaceuticals, Inc. 136. Phillip Jochelson, Somaxon Pharmaceuticals Inc
137. Liz Olek, Achillion Pharmaceuticals, Inc. 138. John Loonsk, CGI Inc.
139. Marilyn Rosa Bray, Grifols, S.A. 140. Laurence Levine, ACCESS PHARMACEUTICALS
141. Larry Dillaha, Insys Therapeutics 142. Mark Bagarazzi, Inovio Pharmaceuticals, Inc.
143. William Andrade, Corrections Corporation of America 144. Arthur Diskin, Royal Caribbean Cruises Ltd.
145. Janis Johnson, Health Net, Inc. 146. Jasen Gundersen, TeamHealth, Inc.
147. James Tursi, AUXILIUM PHARMACEUTICALS, INC. 148. Steven Miller, Express Scripts Holding
149. Catherine Baase, The Dow Chemical Company 150. Andy Wolff, Cytokinetics, Incorporated